Evidence map›Paper›PMID 27746218›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Gretchen A Hoff, Johannes C Fischer, Katharine Hsu, Sarah Cooley, Jeffrey S Miller, Tao Wang, Michael Haagenson, Stephen Spellman, Stephanie J Lee, Markus Uhrberg and 2 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Gretchen A HoffBlood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota.
Johannes C FischerInstitute of Transplantation Diagnostics and Cell Therapeutics, Universitatklinikum Dusseldorf Klinik fur Kinder, Düsseldorf, Germany.
Katharine HsuBlood and Marrow Transplantation, Memorial Sloan Kettering Cancer Center, New York, New York.
Sarah CooleyBlood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota.
Jeffrey S MillerBlood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota.
Tao WangCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
Michael HaagensonCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Stephen SpellmanCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
Stephanie J LeeBlood and Marrow Transplantation, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Markus UhrbergInstitute of Transplantation Diagnostics and Cell Therapeutics, University Clinic of Düsseldorf, Düsseldorf, Germany.
Jeffrey M VenstromBlood and Marrow Transplant, University of California San Francisco Medical Center, San Francisco, California.
Michael R VernerisUniversity of Colorado, Pediatric BMT and Cell Therapy, Aurora, Colorado. Electronic address: michael.verneris@UCDevnver.edu.
University of Minnesota · USDüsseldorf University Hospital · DENational Marrow Donor Program · USFred Hutch Cancer Center · USMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USUniversity of California San Francisco Medical Center · USUniversity of Colorado Denver · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAMER, ERIC G. · 1985 to 2023
$59.0M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune RecoveryR01AI100879 · NIAID · UNIVERSITY OF MINNESOTA · PI VERNERIS, MICHAEL R. · 2013 to 2017
$1.9M
Genetic epidemiology of hematopoietic cell transplant outcomesR01CA196754 · NCI · UNIVERSITY OF MINNESOTA · PI SPECTOR, LOGAN G., VERNERIS, MICHAEL R. · 2015 to 2018
$1.7M
Inducing NK cells to remember and fight cancerR01HL122216 · NHLBI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2018
$1.5M
Medical Student Summer Research Program in Infection and ImmunityT35AI118620 · NIAID · UNIVERSITY OF MINNESOTA · PI MUELLER, DANIEL L · 2015 to 2025
$351k
NCI NIH HHS P01 CA023766NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA196754NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL122216NIAID NIH HHS R01 AI100879NIAID NIH HHS T35 AI118620
6 · The paper itself

Abstract

Natural killer cells are important in graft-versus-leukemia responses after hematopoietic cell transplantation (HCT). A variety of surface receptors dictates natural killer cell function, including killer cell immunoglobulin-like receptor recognition of HLA-C. Previous single-center studies show that HLA-C epitopes, designated C1 and C2, were associated with allogeneic HCT outcomes; specifically, recipients homozygous for the C1 epitope (C1/C1) experienced a survival benefit. Additionally, mismatching at HLA-C was beneficial in recipients possessing at least 1 C2 allele, whereas the opposite was true for homozygous C1 (C1/C1) recipients where HLA-C mismatching resulted in worse outcomes. In this analysis we aimed to validate these findings in a large multicenter study. We also set out to determine whether surface expression of recipient HLA-C, determined by polymorphism in a microRNA (miR-148a/b) binding site within the 3'-region of the HLA-C transcript, was associated with transplant outcomes. In this large registry cohort, we were unable to confirm the prior findings regarding recipient HLA-C epitope status and outcome. Additionally, HLA-C surface expression (ie, surface density), as predicted by the miR-148a/b binding single nucleotide polymorphism, was also not with associated transplant outcomes. Collectively, neither HLA-C surface expression, as determined by miR-148a/b, nor recipient HLA-C epitopes (C1, C2) are associated with allogeneic HCT outcomes.

Indexed as

HaplotypesHematopoietic Stem Cell TransplantationAdolescentAdultAgedBinding SitesChildChild, PreschoolFemaleHLA-C AntigensHumansInfantInfant, NewbornKiller Cells, NaturalMaleMicroRNAsHLA-C AntigensMicroRNAsMIRN148 microRNA, humanAllogeneic transplantHLA-CKIRmiRNANK cells

Identifiers

PMID27746218
PMCPMC5198579
OpenAlexW2531680868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.